TDOC · Teladoc Health, Inc. · Stock research

Current Thesis

The turnaround leg this note tracked from July has failed its own gate. The 2026-07-29 Q2 print was the binary, and it printed on the bear side of every watch item: total revenue $606.9M (-4% YoY), BetterHelp revenue $212.6M (-12% YoY), average paying users 0.346M against Q1's 0.361M, and a full-year revenue guide cut roughly 5% at the midpoint to $2,362-2,447M from the $2,480-2,580M reaffirmed on 2026-04-29. The $8.00 weekly-close level flagged as the post-Walmart-deal shelf gave way; the 2026-08-14 close of $6.81 sits 29.9% under the $9.72 52-week high. What an investor is left underwriting is narrower and less exciting than the July story: a company with $774.3M of cash at 2026-06-30, an unchanged $130-170M free-cash-flow guide, and a mental-health segment mid-way through swapping a shrinking cash-pay book for an in-network one whose economics are not yet visible in the P&L. That is a balance-sheet-and-transition argument, not a re-rating.

Bullish and bearish views on Teladoc Health, Inc.

The model's bull view on Teladoc Health, Inc. (TDOC), in brief: Adjusted EBITDA guidance was reset to $271-303M, a range whose midpoint is close to the prior $267-306M. The bear view: Every segment line moved the wrong way in Q2. Both cases follow in full.

Bull Case

• Adjusted EBITDA guidance was reset to $271-303M, a range whose midpoint is close to the prior $267-306M.
• The demand problem is capacity, per management. On the 2026-07-29 release the CEO said insurance demand outpaced provider capacity and that the company "accelerated the nationwide insurance rollout ahead of plan." If that framing holds, the BetterHelp decline is a supply-side transition cost with a defined end, not terminal churn.
• Integrated Care is still growing and adding covered lives. Segment revenue was $394.3M in Q2 (+1% YoY) with a 16.5% adjusted EBITDA margin; U.S. members reached 100.3M at 2026-06-30; chronic-care enrollment was 1.272M, +14% YoY. The larger half of the business is compounding enrollment even while the consumer half contracts.
• Sell-side targets now sit above the tape rather than below it. Citi cut to $7.50 on 2026-08-03 (from $11), Evercore ISI to $7.50 on 2026-07-30 (from $10), Jefferies to $8 on 2026-07-30 (from $9). In July the stock traded above nearly every target; at $6.81 it trades under those three marks. Stockanalysis.com shows a 17-analyst average of $7.56 with a $5-$11 range as of mid-August 2026.
• Momentum is washed out on the short-term oscillator. RSI(14) was 29.7 at the 2026-08-14 close, the first oversold reading of this leg.

Bear Case

• Every segment line moved the wrong way in Q2. Revenue -4% YoY vs -2% in Q1; net loss $38.9M (-$0.21/sh); adjusted EBITDA $65.7M, -5% YoY. BetterHelp's adjusted EBITDA margin was 0.2% — the segment contributed effectively nothing at the profit line in the quarter.
• The guidance cut was specific and recent. BetterHelp FY2026 revenue was taken to $770-830M from $810-870M, with management citing cash-pay pressure that "accelerated further in late May and into June, beyond our prior assumptions." That timing means the deterioration was already running while the stock made its July high.
• Q3 guidance implies no immediate inflection. Revenue $569-609M and adjusted EBITDA $62-74M for Q3 both bracket levels below the Q2 actuals of $606.9M and $65.7M at the midpoint.
• The Walmart channel did not appear as a quantified driver. The Better Care Services distribution deal (~2026-05-28) that carried the stock 15.8% higher in a session was not accompanied by disclosed ramp metrics in the Q2 release. The catalyst that created the leg has so far produced no reported number.
• Structure is broken, and the prior break level is now overhead. The $8.00 shelf that defined the post-deal base is above the market; a stock that loses its breakout base after a guidance cut typically needs a new sponsor, and none is dated.

Setup & Price Structure

• 2026-08-14 close $6.81; 52-week high $9.72; drawdown -29.9%. Three-month return is still +7.1%, meaning the entire remaining gain belongs to the May-July leg and the post-print decline has retraced most of it.
• The $8.00 weekly-close level named as the invalidation in the prior note broke after 2026-07-29. That level is now resistance rather than support, and reclaiming it on a weekly close is the cleanest evidence that the transition story is being re-underwritten.
• Downside reference is the $4.40 52-week low. Between $6.81 and that low there is no dated shelf from this cycle other than the pre-Walmart-deal zone the stock occupied before ~2026-05-28.
• Positioning observables: three price-target cuts inside six sessions (2026-07-30 Jefferies and Evercore ISI, 2026-08-03 Citi), all landing at or below $8; RSI(14) 29.7; no earnings date inside the next 30 days, so the calendar offers no scheduled forcing event to compress the range.
• The narrative is dead for the leg as constructed. The narrative that priced from ~2026-05-28 (Walmart distribution) through the 2026-07-08 renewed-attention coverage and the July high failed its verification event on 2026-07-29 and lost the structure that defined it. A different, slower argument — in-network BetterHelp reaching scale — may build later, but it has no dated evidence yet and no confirmed base.

Catalyst Calendar (next 30 days)

• No confirmed company catalyst between 2026-08-15 and 2026-09-14. Q2 results were released 2026-07-29 and the Q3 report has not been scheduled as of this writing; on prior-year cadence it lands in late October (~2026-10-28, est.).
• ~2026-10-28 (est.) — Q3 2026 results. First checkpoint against the Q3 guide of $569-609M revenue / $62-74M adjusted EBITDA, and the first read on whether BetterHelp paying users stabilize versus Q2's 0.346M.

Elapsed catalysts

• Ongoing, undated — nationwide BetterHelp in-network rollout. Management said on 2026-07-29 it was accelerated ahead of plan; any interim disclosure of covered-lives or in-network visit volume would arrive outside the earnings calendar. (passed 28d ago)
• Ongoing, undated — analyst revisions. The cluster of cuts on 2026-07-30 and 2026-08-03 reset the target range; further moves would come without a fixed date. (passed 23d ago)

What Would Change Our Mind

The structure that defined the bull leg is already gone — the $8.00 shelf broke after the 2026-07-29 print and the FY revenue guide was cut, so the July thesis has been settled against, not left pending. What would rebuild a case is narrow and checkable: a weekly close back above $8.00 that reclaims the broken shelf, or a Q3 report (~late October) showing BetterHelp paying users at or above 0.346M with the FY revenue range held at $2,362-2,447M rather than cut again. Evidence that in-network revenue is replacing cash-pay dollars — a disclosed in-network revenue figure, or BetterHelp segment adjusted EBITDA margin back toward the 3.0-4.6% full-year band from Q2's 0.2% — would matter more than any single revenue line. On the downside, a weekly close below $6.00 round-trips the entire Walmart-deal re-rating and puts the stock back into the $4.40-$6 zone it occupied before 2026-05-28; a second consecutive FY guidance cut at the Q3 print would confirm that the transition is destroying more revenue than it is converting.

Correlation Notes

• The drawdown dates to the 2026-07-29 print and the guidance cut, not to a sector-wide event; readers separating company-specific damage from sector beta can compare the same 2026-07-29-to-2026-08-14 window against other consumer-telehealth and virtual-care names before attributing the move.
• The two segments do not correlate with the same things. Integrated Care (100.3M U.S. members, 1.272M chronic-care enrollees at 2026-06-30) tracks employer and health-plan benefit budgets and renewal cycles; BetterHelp tracks consumer discretionary spending and, increasingly, behavioural-health reimbursement policy. Consolidated revenue averages two different exposures.
• With a $774.3M cash position and a maintained $130-170M FCF guide against a mid-single-digit-dollar share price, the equity behaves partly as a balance-sheet story, which links it to small-cap unprofitable-healthcare risk appetite rather than to managed-care fundamentals.
• Reimbursement headlines for behavioural health — payer coverage decisions, telehealth parity rules — are now a direct input to the BetterHelp line in a way they were not under the cash-pay model.